Hikma debuts labetalol hydrochloride in dextrose injection, sodium chloride injection

Hikma is offering labetalol hydrochloride 1mg/mL in 200-ml dextrose injection and 100-, 200- and 300-mL in sodium chloride injection.

Labetalol HCl in sodium chloride injection and labetalol HCl in dextrose injection are indicated for severe hypertension, to lower blood pressure.

Labetalol HCl injection, 100 mg/20 ml and 200 mg/40 ml vial had a market value of approximately $6 million in the 12 months ended March 2021, according to IQVIA.

“We are proud to introduce the first generic Labetalol HCl Injection in ready-to-use bags, a new therapeutic entity used to treat severe hypertension,” said Riad Mishlawi, Hikma president of Injectables. “Ready-to-use formulations improve the speed and safety of patient care and help hospitals, pharmacists, doctors and nurses treat patients more easily and with reduced risk of medication preparation error. This is another example of how Hikma is using its capabilities as a leading generic pharmaceutical company to expand its portfolio of essential medicines and introduce delivery systems that serve the growing needs of U.S. medical professionals and their patients.”